AngioDynamics - ANGO Stock Forecast, Price & News

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Raymond James dropped their target price on shares of AngioDynamics from $32.00 to $27.00 and set a "strong-buy" rating on the stock in a research note on Wednesday, July 13th. TheStreet lowered AngioDynamics from a "c-" rating to a "d+" rating in a report on Friday, July 8th. Finally, Canaccord Genuity Group lowered their target price on AngioDynamics from $40.00 to $35.00 in a research note on Wednesday, July 13th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $33.00.

AngioDynamics Stock Performance

Shares of ANGO Stock opened at $23.45 on Wednesday. The firm's 50 day moving average is $20.62 and its 200 day moving average is $21.36. The stock has a market capitalization of $913.85 million, a P/E ratio of -34.48 and a beta of 0.90. AngioDynamics has a 12 month low of $17.56 and a 12 month high of $32.00. The company has a current ratio of 1.93, a quick ratio of 1.24 and a debt-to-equity ratio of 0.06.

AngioDynamics (NASDAQ:ANGO - Get Rating) last posted its quarterly earnings results on Tuesday, July 12th. The medical instruments supplier reported $0.01 EPS for the quarter, hitting analysts' consensus estimates of $0.01. AngioDynamics had a negative return on equity of 0.04% and a negative net margin of 8.40%. The firm had revenue of $87.00 million during the quarter, compared to analyst estimates of $82.91 million. AngioDynamics's revenue was up 13.3% compared to the same quarter last year. On average, sell-side analysts anticipate that AngioDynamics will post 0.03 earnings per share for the current year.

Insider Buying and Selling at AngioDynamics

In other news, SVP Dave Helsel sold 5,000 shares of the stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $22.44, for a total value of $112,200.00. Following the sale, the senior vice president now directly owns 23,822 shares of the company's stock, valued at $534,565.68. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 4.80% of the company's stock.